Recent News

• 04.24.2025 - “A New Way to Treat Brain Cancer?” by Andrew Brenner, MD, PhD
• 04.23.2025 - Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
• 04.23.2025 - Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
• 04.22.2025 - Kyle Guse
• 04.22.2025 - Kyle Guse
• 04.15.2025 - Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases
• 04.15.2025 - Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases
• 03.27.2025 - PLUS THERAPEUTICS FOURTH QUARTER 2024 RESULTS CONFERENCE CALL
• 03.27.2025 - PLUS THERAPEUTICS FOURTH QUARTER 2024 RESULTS CONFERENCE CALL
• 03.27.2025 - Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Recent Filings

• 04.23.2025 - S-3/A Registration statement under Securities Act of 1933
• 04.18.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 04.18.2025 - 8-K Current report
• 04.11.2025 - POS AM Post-Effective amendments for registration statement
• 04.10.2025 - DEF 14A Other definitive proxy statements
• 04.04.2025 - S-3 Registration statement under Securities Act of 1933
• 04.01.2025 - PRER14A Preliminary Proxy Soliciting materials
• 03.31.2025 - RW Registration Withdrawal Request
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]